icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
Safety & Efficacy of Boceprevir/PegInterferon/Ribavirin (BOC/P/R) Combination Therapy for Chronic HCV G1 Patients with Compensated Cirrhosis: A Meta-Analysis of Five Phase 3 Clinical Trials
 
 
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
J.M. Vierling1*, S. Zeuzem2, F. Poordad3, J.-P. Bronowicki4, M.P. Manns5, B.R. Bacon6, R. Esteban7, S.L. Flamm8, P.Y. Kwo9, L.D. Pedicone10, W. Deng11, F.J. Dutko11, M.J. DiNubile11, K.J. Koury11, F.A. Helmond11, J. Wahl11, S. Bruno12 1Baylor College of Medicine, Houston, TX, USA, 2JW Goethe University Hospital, Frankfurt, Germany, 3Texas Liver Institute/University of Texas Health Science Center, San Antonio, TX, USA, 4University Henri Poincare of Nancy, Vandoeuvre-lès-Nancy, France, 5Medical School of Hannover, Hannover, Germany, 6Saint Louis University School of Medicine, St. Louis, MO, USA, 7Vall d'Hebron University Hospital, Barcelona, Spain, 8Northwestern Feinberg School of Medicine, Chicago, IL, 9Indiana University School of Medicine, Indianapolis, IN, 10Merck Sharp & Dohme Corp. (former employee), 11Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 12A.O. Fatebenefratelli e Oftalmico, Milan, Italy

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif